Accuray Up 10% After Receiving FDA Clearance (ARAY)

Shares of Accuray Incorporated

are up almost 10% this morning, after the company received FDA clearance for its CyberKnife® System's lung optimized treatment. Lung Optimized Treatment offers the accuracy and steep dose fall off required to safely treat lung tumors, even those close to such critical structures. Simulation and comparison workflows, combined with unique tracking modes, allow the clinician to select from multiple, non-invasive options, providing lung SBRT patients the optimal non-invasive treatment option, regardless of tumor location. "Lung Optimized Treatment is a new tool we developed to meet the clinical demand for more flexibility in treating lung cancer patients with radiosurgery and the desire to move away from reliance on fiducial markers," said Chris A. Raanes, senior vice president and chief operating officer for Accuray. "This new technology enables treatments throughout the lung without a single incision, all while safeguarding healthy tissue and structures around the tumor to ensure they are not damaged by radiation." At last check, shares of ARAY were up 60 cents to $6.85.